


## **Keynote: Intellectual Property Issues in Life Sciences Applications of Nanotechnology**

**Ahmed Mousa**

Pieris Pharmaceuticals, Inc. Boston USA, GmbH Munich Germany

---

**Ahmed Mousa** is a biotechnology entrepreneur with experience in business and corporate development, licensing, intellectual property, corporate legal and governance. Ahmed currently serves as Senior Vice President, Chief Business Officer and General Counsel of Pieris Pharmaceuticals, acting as site head for the Company's Boston office, overseeing the business development, portfolio strategy, and quality assurance functions, and leading Pieris' intellectual property, corporate secretary, and legal activities, including licensing and corporate legal as well as the Company's global patent portfolio. Mr. Mousa also previously oversaw the Company's centralized project leadership function. Prior to joining Pieris, Mr. Mousa was an attorney with the law firm Covington & Burling LLP, where he represented pharmaceutical and biotechnology companies in a range of matters. He was also previously a law clerk at the U.S. Court of Appeals for the Third Circuit and an IP Associate at the law firm Kirkland & Ellis LLP. Mr. Mousa obtained undergraduate degrees in Molecular Biology and Government from Cornell University and a master's degree in Biotechnology from Johns Hopkins University. His research experience prior to his legal career focused on tumor biology and angiogenesis. Mr. Mousa graduated from Georgetown Law with honors, where he was the Editor-in-Chief of the Georgetown Journal of International Law.



---

### **ABSTRACT**

The complexity of biomedical nanotechnologies yields correspondingly complex intellectual property issues. This talk will examine the challenges faced when seeking to patent these innovations. These challenges include use of known materials as part of these new products, interdisciplinary innovations that draw on multiple fields, and the presence of broad blocking patents in the field. The talk will also discuss strategies to effectively address these challenges to capture commercially significant intellectual property rights to nanomedicines and other nanotechnology innovations in the life sciences.